Donald W. DeGolyer - Sep 16, 2022 Form 4 Insider Report for TYME TECHNOLOGIES, INC. (TYME)

Role
Director
Signature
By: /s/ Richard Cunningham as attorney-in-fact for Donald W. DeGolyer
Stock symbol
TYME
Transactions as of
Sep 16, 2022
Transactions value $
$0
Form type
4
Date filed
9/16/2022, 06:00 PM
Previous filing
Aug 29, 2022
Next filing
Oct 5, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYME Director Stock Option - Option to buy Disposed to Issuer -100K -100% 0 Sep 16, 2022 Common Stock 100K $2.90 Direct F1
transaction TYME Director Stock Option - Option to buy Disposed to Issuer -50K -100% 0 Sep 16, 2022 Common Stock 50K $2.33 Direct F2
transaction TYME Director Stock Option - Option to buy Disposed to Issuer -50K -100% 0 Sep 16, 2022 Common Stock 50K $1.18 Direct F3
transaction TYME Director Stock Option - Option to buy Disposed to Issuer -65K -100% 0 Sep 16, 2022 Common Stock 65K $1.22 Direct F4
transaction TYME Director Stock Option - Option to buy Disposed to Issuer -88K -100% 0 Sep 16, 2022 Common Stock 88K $1.10 Direct F5
transaction TYME Director Stock Option - Option to buy Disposed to Issuer -88K -100% 0 Sep 16, 2022 Common Stock 88K $0.31 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Donald W. DeGolyer is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 4,382 shares of Syros common stock for $66.18 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split").
F2 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $53.17 per share, after giving effect to the Reverse Split.
F3 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split.
F4 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split.
F5 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split.
F6 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.